Novo Nordisk is facing a massive wave of generic competitors to its injectable formulations of GLP-1 agonist semaglutide, used to treat diabetes and obesity, as a key patent in India is due to expire ...
Overview Java backend roles in 2026 demand strong fundamentals plus expertise in modern frameworks like Spring Boot and ...
In today’s fast-changing digital economy, businesses need more than standard tools to stay ahead. Customers expect speed, ...
Natco Pharma Ltd. is set to launch the generic version of Ozempic at a price that's 90% cheaper than the original created Novo Nordisk A/S, triggering a price war for weight-loss drugs in India as the ...
Access to affordable medicines remains one of the biggest challenges in healthcare systems worldwide, especially in low- and middle-income countries. In India, where a significant portion of medical ...
The Go team has approved generic methods, reversing a longstanding position in the language's FAQ. The proposal, from Go co-designer Robert Griesemer, now moves to implementation. A key issue – that ...
In 2026, Novo Nordisk’s patent on semaglutide will expire in several countries, including India and China. Generic-drug makers are poised to flood these markets with inexpensive products. Industry ...
A monthly overview of things you need to know as an architect or aspiring architect. Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with ...
WASHINGTON (AP) — Federal officials have approved another generic version of the abortion pill mifepristone, a regulatory formality that quickly triggered pushback from anti-abortion groups and ...
AbbVie ABBV0.05%increase; green up pointing triangle has struck a deal with generic drugmakers aimed at extending patent protection for its blockbuster autoimmune drug Rinvoq well into the next decade ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results